We're searching for the                     healthcare companies of tomorrow.

 

The OneVentures Biomedical Translational Fund team is on the road with Jim Scopa, formerly of MPM Capital and currently a fellow at Stanford, to scout for the transformative healthcare companies of tomorrow.


 

Part one: "How to make your project investable."

Over breakfast, gain insight into the US perspective on the healthcare market from veteran venture capitalist Jim Scopa, and how Australian companies can position themselves to succeed on the global stage. Get to know the OneVentures' healthcare team at the panel discussion and Q&A session that follows. 
 

Part two: Pitch meetings.

Pitch your company or project to a member of our team privately. We are actively seeking to invest from our AU$170M Biomedical Translational  in companies commercialising medical devices, diagnostics and pharmaceuticals.

 

 

7, 8 and 11 September 2017

8:30am - 2:00pm

 
 
Not a healthcare company? We'd still like to hear from you. Submit an inquiry here.
background-2462436_1920.jpg

Meet the OneVentures panel

Paul 1.jpg

Paul Kelly

 

Anne-Marie Birkill

Graeme1.jpg

Dr Graeme Wald

Amir1.jpg

Dr Amir Zalcenstein

ONEV_PREVIEWS-30.jpg

Sarah Meibusch

Sakura Holloway

Meet Jim Scopa

Jim has recently joined the Advisory Panel for the Sydney, Australia based $170M OneVentures Healthcare Fund III.

Jim has recently joined the Advisory Panel for the Sydney, Australia based $170M OneVentures Healthcare Fund III.

Currently a fellow at Stanford University, Jim Scopa, J.D. M.B.A. has led investments in biopharmaceuticals, medical devices and diagnostics since the 1990’s.  He currently serves on the boards of Astute Medical, Blade, Conatus (CNAT), Semma Therapeutics and True North Therapeutics.  He previously served on the boards of Peplin (acquired by LEO Pharmaceuticals), iPierian (acquired by Bristol Myers Squibb), Trivascular (acquired by Endologix), Solasia KK and Nevro (NVRO).

In his last role prior to joining Stanford, Jim was a Managing Director at MPM Capital, one of the leading Life Science venture capital firms in the US.  Before that, Jim spent 18 years in health care investment banking advising numerous life sciences companies on financings and mergers and acquisitions. Jim spent the bulk of his career at Alex. Brown and Sons, and following its acquisition by Deutsche Bank, served as Global Co-Head of Health Care Investment Banking from 1999 to 2002.  From 2002 to 2005 Jim served as Co-Head of Health Care Investment Banking at Thomas Weisel Partners, where he was a member of the Investment Committee for the firm’s health care venture fund.  Jim graduated from Harvard College A.B. History and Science (Biology) and went on to complete the J.D.-M.B.A. program at Harvard Law School and Harvard Business School.  Jim is currently a Fellow at Stanford University’s Distinguished Careers Institute, where he is focusing on innovations in regenerative and translational medicine.


 


Register your interest

 

Sydney

7 September 2017

DibbsBarker, 123 Pitt St, Sydney

Melbourne

8 September 2017

FB Rice, 14/90 Collins St, Melbourne

Brisbane

11 September 2017

The Precinct, 315 Brunswick St, Fortitude Valley

 

Note: You are invited to register for  all sessions. If registering for more than one location, please ensure you are logged out of the previous portal. 

background-2462431_1920.jpg

Event schedule.

8:30am - 9:00am                                                          

 

9:00am - 9:30am

                                                                              

9:30am - 10:00am

Breakfast and briefing by Jim Scopa.

An experienced investor and engaging speaker, Jim will reflect on trends in the healthcare sector in the world’s largest market, the US, and how emerging Australian healthcare companies need to position themselves to succeed on the global stage.

Panel and Q&A session.

Get to know the OneVentures Healthcare team. We'll focus the panel around our experiences as entrepreneurs, how to be a promising venture investee and how to get "investment ready".

Meet and greet.

An opportunity to network with other attendees and emerging healthcare companies.


10:00am - 1:30pm

Private meetings.

Pitch your company or project one-on-one to a member of the team to discover growth and partnership opportunities. Meetings are appointment only, please see registration details above.


 
 
Make your project investable
 

The Briefing with Jim Scopa. 

We're pleased to invite you to a unique breakfast event across three cities: Sydney, Melbourne and Brisbane. Delivered by Jim Scopa, and alumnus of MPM Capital, the presentation will focus on how to "make your project investable". MPM is a US-based venture capital firm with US$2.6B in assets under management. Jim has recently scaled back his involvement in the company to join the faculty of Stanford University, where he is focusing on the translation and commercialization of early stage healthcare projects. 

An engaging and informative speaker, Jim will reflect on trends in the healthcare sector in the world’s largest market, the US, and how emerging Australian healthcare sector companies need to position themselves to succeed on the global stage.

Following Jim’s presentation, members of the OneVentures Investment Team will join him for a facilitated Q&A session with the audience, to offer expertise around how VC's evaulate if a company is "investable", and how to get "investment ready". We're also experienced entrepreneurs who have a wealth of insight to share on growth, partnering and navigatng the VC landscape.

 
 
 

 

One-on-one meetings with the healthcare team. 

Selected biomedical companies will then meet privately with members of the OneVentures Investment Team, for an opportunity to pitch their projects and companies. OneVentures recently launched its $170M Healthcare Fund III and is looking to invest $10 to $20 million in Australian domiciled companies commercialising medical devices, drugs in clinical development or diagnostics. This is a fantastic opportunity to discuss your company or research project, and discover growth and partnership opportunities.

 
 

 

About OneVentures.

OneVentures is an Australian venture capital firm with $320M under management launching its first fund in 2010. A global growth focus drives investment selection with portfolio companies addressing multi-billion dollar problems. Existing healthcare sector portfolio companies include Hatchtech, Vaxxas, Clinical Genomics Technologies and Prota Therapeutics.

OneVentures recently launched its $170M Healthcare Fund III, which is focused on investing in therapeutics, devices or diagnostics at or near clinical development with a clear commercial, regulatory and reimbursement pathway; and well defined value inflection and exit points on deal entry. The OneVentures' team has deep experience in driving opportunities through the FDA regulatory process and commercialising biomedical innovations in global markets. 

The fund launched in December 2016 and is licenced under the Commonwealth government’s Biomedical Translation Fund (BTF) programme. The BTF programme was established to provide a pool of public and private funds for investment in promising biomedical innovations with commercialisation potential managed by leading Australian venture firms. OneVentures was granted an $85 million license supported by matching capital from its private investor network. The government funding provides benefits to investors both during the investment phase and on realisation. 

The fund will invest $10 to $20 million in Australian domiciled companies commercialising medical devices, drugs in clinical development or diagnostics.

For more on OneVentures, visit our website.